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1. Introduction
Therapy-related acute myeloid leukemia (t-AML) is a heterogeneous group of myeloid neo‐
plasms occurring as an overwhelming complication in patients receiving previous cytotoxic
chemotherapy and/or radiation therapy used to treat haematopoietic or solid malignancies
or associated with immunosuppressive treatment for non-neoplastic rheumatologic/autoim‐
mune diseases or solid organ transplantation (Offman et al., 2004; Kwong, 2010). T-AML is
an increasingly recognized condition included in the category of therapy-related myeloid
neoplasms in the revised WHO classification of tumours of haematopoietic and lymphoid
tissues, together with therapy-related myelodysplastic syndrome (t-MDS) and myelodys‐
plastic/myeloproliferative neoplasm, that constitute a unique clinical syndrome (Vardiman
et al., 2009).
The average age of the population in the developed countries is increasing, and cancer inci‐
dence increases with age. Both improved early detection of first malignancies and primary
oncologic therapy have led to enhanced survival rates, and the risk of t-AML has conse‐
quently risen over the last few decades (Travis, 2006; Ries et al., 2008). Thus patients are, in a
sense, the fortunate victims of our own success. Secondary leukemias challenge both the un‐
derstanding of leukemogenesis and the clinical management of these conditions. The dis‐
ease offers a unique opportunity to study leukaemic transformation by relating specific
genetic and molecular abnormalities to the biologic effects of particular agents. The detailed
insights into pathogenetic mechanisms will eventually help to establish a more differentiat‐
ed clinical approach to successfully treat, but hopefully also prevent, these often fatal conse‐
quences of cytotoxic therapies. Despite that t-AMLs share common phenotypic features with
de novo AML, the prognosis is generally unfavorable.
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In general, t-AML are of particular importance to study for several reasons: (i) they repre‐
sent the most serious long-term complications to current cancer therapy and the under‐
standing would help to identify patients at risk in order to tailor therapy; (ii) they can be
directly induced by chemically well-defined agents or irradiation with well-known cellular
effects; (iii) they present the same chromosome aberrations and gene mutations as de novo
AML, allowing for extrapolation of results from one to the other type of disease thus clarify‐
ing the biological processes leading to leukemogenesis; (iv) an early stage of MDS with re‐
fractory cytopenia is often diagnosed in therapy-related diseases, because most patients are
followed thoroughly after intensive chemotherapy or irradiation, while in de novo AML,
such information is often lacking; (v) there is still no consensus on the therapeutic manage‐
ment.
2. Epidemiology
The proportion of therapy-related AMLs varies from 5% to higher than 10% out of all cases
of AMLs depending on the primary disease and the applied treatment in regard to chemical
structure and dose of the used compounds, as well as to the type and intensity of used phys‐
ical agent (Schneider et al., 1999). The GIMEMA registry reports an incidence of 5% of AML
occurring as a second malignancy in Italy, however this registry includes only patients in
whom treatment is feasible. Similarly, t-AML account for about 6% of all new AML cases in
the UK, thus corresponding to an incidence rate at around 0.2/100 000/year (reviewed in
Seedhouse & Russell, 2007). For a 12-years period, the review of our own data also showed
that in 26 out of 407 consecutive cases of adult AML diagnosed and treated in our institution
had a history for a previous malignancy treated with chemotherapy and/or radiotherapy
which accounts for 6,1% (Balatzenko & Guenova, 2012). Higher values were reported by
others as the pooled analysis of a consecutive series of 372 Swedish adult AML cases com‐
pared to 4230 unselected cases reported in the literature 1974 – 2001 revealed an incidence of
13% and 14%, respectively (Mauritzson et al.,2002).
2.1. Age
All age groups are affected - both children and adults develop AML following treatment
with antineoplastic agents. However, children deserve particular consideration, taking into
account the long life-expectancy of oncological patients cured by chemo and radiotherapy
(Le Deley et al., 2003). As demonstrated in the published literature, the risk of developing
AML following chemotherapy is not reliably correlated with the age of the pediatric patient.
There is no consistent evidence that indicates that younger children will be at increased risk;
in fact, some studies suggest that younger children might actually display a decreased sus‐
ceptibility. Unlike secondary solid tumors such as breast, central nervous system, bone, and
thyroid cancer which are highly dependent on the age of the patient at time of diagnosis and
treatment; an age dependency for t-AML risk was not observed in the same pediatric patient
populations (reviewed in Pyatt et al., 2007). In addition, though in the Guidelines for Carci‐
nogen Risk Assessment (2005), presented at the Risk Assessment Forum U.S. Environmental
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Protection Agency a 10-fold higher risk attributable to early-life carcinogenic exposure was
assumed, leading to a reasonable expectation that children can be more susceptible to many
carcinogenic agents, the available scientific and medical literature does not support the hy‐
pothesis that children necessarily possess an increased risk of developing AML following
leukemogenic chemical exposure (Pyatt et al., 2007, Barnard et al, 2005).
In adult patients there is a higher risk and shorter latency period for the development of t-
AML (Dann et al., 2001). In general, there is no convincing evidence for gender predisposi‐
tion (Pagano et al., 2001; Smith et al. 2003).
2.2. Primary malignancies
Due to decreasing overall death rates in cancer there is an increasing number of cured pa‐
tients at risk of developing t-AML. The review of reports on long follow-up of high numbers
of patients treated with relatively uniform protocols comprising cytotoxic drugs, growth fac‐
tors and radiation therapy individually or in combination highlights the major trends, with
the greatest likelihood of developing therapy-related myeloid neoplasms following treat‐
ment of hematopoietic malignancies and breast cancer in adults, ALL and central nervous
system tumors in children, germ cell tumours, lung cancer, etc. A significant proportion of t-
AMLs nowadays involve patients treated for non-neoplastic disorders, and those treated
with high-dose chemotherapy followed by autologous stem cell transplantation (Mauritzson
et al., 2002; Suvajdžić et al. 2012; Ramadan et al., 2012). Representative studies are summar‐
ised in Table 1 demonstaring the incidence of t-AML in different primary diseases.
2.2.1. Hematologic malignancies
Up to 10% of patients with a preceeding lymphoid neoplasm treated with conventional che‐
motherapy and especially high-dose therapy and autologous stem cell transplantation may
develop a t-AML within 10 years following primary therapy (Table 1). In patients with
Hodgkin lymphoma (HL), the risk of t-AML has been reported to range between 1% and
10%, depending on the type of therapy administered, the study population size, and the fol‐
low-up duration. In patients with non-Hodgkin’s lymphoma (NHL), an increased risk of
secondary malignancies including therapy-related myeloid neoplasms has been reported, in
particular when fludarabine-containing regimens or SCT are used. Significant risk factors
were older age at the time of diagnosis, male sex, and fludarabine- or nucleoside analogs-
containing therapy or SCT.Interestingly, leukemia cases are rarely or never seen in patients
treated with radiotherapy alone (Mudie et al. 2006). Secondary carcinogenesis remains a ma‐
jor late complication in patients with acute lymphoblastic leukemia, particularly in children.
A retrospective study of the cumulative incidence of secondary neoplasms after childhood
ALL over 30 years showed that the risk of t-AML is higher in ALL children who receive a
high cumulative dose and prolonged epipodophyllotoxin therapy in weekly or bi-weekly
schedules, with short-term use of G-CSF and central nervous system irradiation as additive
risk factors (Hijiya et al.,2007).
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Primary Disease
Number of
patients in
the study
Number of
patients with
t-AML
Therapy MedianLatency References
Hematological Malignancies
Acute lymphoblastic
leukemia (adults)
641 6 (0.9%) CT 32 months Verma et al.,2009
Acute lymphoblastic
leukemia (children)
733 13 (1.8%) CT 3 years Pui et al.,1989
Acute lymphoblastic
leukemia (children)
1290 37 (2,9%) CT 3.8 years Hijiya et al., 2007
Acute lymphoblastic
leukemia
1494 6 (0.4%) CT 1.3 years Tavernier et al.,2007
CLL 521 3 (0.6%) CT 34 months Morrison et al.,2002
B-NHL; T-NHL; Hodgkin’s
lymphoma
1347 11 (0.8%) HDCT±
MoAbs
Tarella et al.,2011
NHL 230 11 (4.8%) HD CT + RT 4.4 years Micallef et al.,2000
NHL 29153 29 (0.1%) RT ± CT;
other
61 months Travis et al.,1991
Hodgkin’s lymphoma 5411 36 (0.7%) RT ± CT 5 years Josting et al.,2003
Hodgkin’s lymphoma 2676 17 (0.6%) RT; CT; RT
+CT
79.9 months Devereux et al.,1990
Hodgkin’s lymphoma 29552 143 (0.5%) RT; CT; RT
+CT
ND Kaldor et al.,1990
Hodgkin’s lymphoma 947 23 (2.4%) RT; CT; RT
+CT
58 months Cimino et al. ,1991
Hodgkin’s lymphoma 32591 169 (0.5%) RT; CT; RT
+CT
ND Dores et al.,2002
Hodgkin’s lymphoma
(children)
1380 24 (1.7%) RT; CT; RT
+CT
ND Bhatia et al.,1996
Hodgkin’s lymphoma 794 8 (1.0%) RT; RT+CT 5 years Mauch et al., 1996
Multiple Myeloma 8740 39* (0.4%) CH, HDM-
ASCT, IMiDs
45.3 months Mailankody et al.,2011
Multiple Myeloma 2418 5 (0.2%) CH, HDM-
ASCT, IMiDs
ND Barlogie et al.,2008
APL 77 3 (3.9%) CT ± ATRA Latagliata et al.,2002
Solid Tumors
Small cell lung carcinoma 158 3 (1.9%) 2.7 years Chak et al.,1984
Germ-cell tumours 212 4 (1.9%) CT ND Pedersen-Bjergaard et
al.,1991
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Primary Disease
Number of
patients in
the study
Number of
patients with
t-AML
Therapy MedianLatency References
Germ-cell tumours 442
174
124
3 (0.7%)
3 (1.7%)
0
CT
RT+CT
RT
ND Schneider et al.,1991
Germ-cell tumors (children) 716
416
6 (0.84%)
0
CT+RT
RT or S
101 weeks Schneider et al.,1999
Ovarian Cancer 63359 109 (0.2%) CT 4 years Vay et al.,2011
Ovarian Cancer 99113 95 (0.1%) RT; CT; RT
+CT
4-5 years Kaldor et al.,1990
Ovarian Cancer 28971 1 (0.003%)
65 (0.2%)
25 (0.09%)
RT
CT
RT+CT
3.3 years Travis et al.,1999
Breast Cancer 5299
646
27 (0.5%)
5 (0.8%)
CT
RT
ND Fisher et al.,1985
Breast Cancer 82700 74 (0.09%) CT; RT; CT
+RT
5 years Curtis et al.,1992
Breast Cancer 1474 14 (0.9%) CH ± RT 66 months Diamandidou et al.,
1996
Testicular Cancer 1909 3
1
2
CT
RT
RT+CT
7.7 years van Leeuwen et al.,
1993
Testicular Cancer 28843 27 (0.09%) CH; RT ND Travis et al.,1997
Prostate Cancer 487 3 (0.6%) CH 48 months Flaig et al.,2008
Prostate Cancer 168612 184 (0.1%) RT Ojha et al., 2010
Auto-immune diseases
Reumatoid arthritis 53067 68 (SIR=2,4) ND Askling et al. 2005
Reumatoid arthritis 4160 0 (SIR=0) TNF
antagonist
NA Askling et al. 2005
Multiple sclerosis 2854 21(SIR=1,84) NA Martinelli et al. 2009
Systemic lupus
erythematodis
5715 8(OR=1,2) ND Loststrone et al. 2009
Wegener’s granulomatosis 293 (SIR=19,6) 6,8-18,5 yrs Faaurschou et al. 2008
Ulcerative colitis 2012 (OR=3,8) ND Johnson et al. 2012
Legend: * including terapy-related MDS; ND – no data; CT – chemotherapy; RT – radio therapy; IMiDs – Immunomodu‐
latory drugs; MoAbs – monoclonal antibodies; HD – high dose; ASCT - autologous stem cell transplantation; ND – no
data; S – surgery; ATRA - all-trans retinoic acid; NHL – non-Hodgkin’s lymphoma; APL – acute promyelocytic leukaemia;
OR – odds ratio; SIR – standardized incidence ratio.
Table 1. Representative studies of the incidence of t-AML in different primary diagnoses.
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2.2.2. Solid tumours
In most studies, an increased risk of t-AML was reported in breast cancer patients treated
with chemoradiotherapy ± radiotherapy. Besides, an increased incidence of t-MDS/AML in
patients treated with surgery alone and in patients with a family history of breast cancer
suggests a possible association between the two diseases.
When looking at solid tumors, an increased risk of t-AML has been reported in breast cancer
patients treated with chemoradiotherapy ± radiotherapy (Table 1). Praga et al. analyzed
9796 breast cancer patients treated in 19 randomized trials (Praga et al., 2005). The cumula‐
tive 8-year risk of t-AML showed wide variability between patients treated with standard or
high cumulative doses of epirubicin (0.37% vs 4.97%, respectively). In almost 400,000 breast
cancer patients, significant risk factors were also younger age at the time of breast cancer di‐
agnosis, advanced stage disease with distal involvement and treatment using radiotherapy
(Martin et al., 2009).A large proportion of patients with testicular cancer can be cured by ra‐
diochemotherapy, including topoisomerase II inhibitors and cisplatin, but t-MDS/AML rep‐
resents a major problem with a mean cumulative risk of 1.3 to 4.7% at 5 years (Travis et al.,
2000). An increased incidence of AML was found in children with non-testicular germ cell
tumors after chemoradiotherapy, with a cumulative incidence in patients treated with com‐
bined chemotherapy and radiotherapy. No cases of leukemia were found in patients treated
with radiotherapy or surgery only (Schneider et al.,1999).
2.2.3. Hematopoietic stem cell trasplantation
An increased risk of therapy-related myelodysplastic syndrome and t-AML after high-dose
therapy and autologous stem-cell transplantation (ASCT) for malignant lymphoma has been
described by several studies, reporting a highly variable incidence ranging from 1-3% (Lenz
et al., 2004; Howe et al., 2003) to 12% (Micallef et al., 2000). The incidence of therapy-related
myeloid neoplasms after SCT is related to the type of conditioning regimens, as patients re‐
ceiving the combination of TBI and alkylating agents seem to have an especially increased
risk, but also to the type of previous chemotherapy, its effects on harvested hematopoietic
stem cells and the use of growth factors. The development of t-MN after SCT has been
shown to be associated with and preceded by markedly altered telomere dynamics in hema‐
topoietic cells, which may reflect increased clonal proliferation and/or altered telomere regu‐
lation in premalignant cells (Chakraborty et al., 2009). In the allogeneic bone marrow or
hematopoietic stem cell transplantation setting, donor cell–derived leukemias (DCL) and
myelodysplastic neoplasms represent a rare but intriguing form of leukemogenesis. DCL
represents a unique form of leukemogenesis in which normal donor cells become trans‐
formed into an aggressive leukemia or MDS following engraftment in a foreign host envi‐
ronment (Wang et al., 2011; Sala-Torra et al., 2006).
2.2.4. Auto-immune diseases
The risk of developing therapy-related AML also applies to patients with non-malignant
conditions, such as autoimmune diseases treated with cytotoxic and/or immunosuppressive
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agents. There is considerable evidence to suggest an increased occurrence of hematologic
malignancies in patients with autoimmune diseases compared to the general population,
with a further increase in risk after exposure to cytotoxic therapies. Unfortunately, studies
have failed to reveal a clear correlation between leukemia development and exposure to in‐
dividual agents used for the treatment of autoimmune diseases. The association of t-AML
and autoimmune diseases was clearly demonstrated in a recent study reporting for an odds
ratio of AML OR=1,29 (95% CI, 1.2–1.39) by comparing 13,486 patients aged over 67 years
with myeloid malignancies to 160,086 population-based matched controls using the SEER-
Medicare database of Hematopoietic Malignancy Risk Traits (SMAHRT). Specifically, AML
was associated with rheumatoid arthritis (OR 1.28), systemic lupus erythematosus (OR 1.92),
polymyalgia rheumatica (OR 1.73), autoimmune haemolytic anaemia (OR 3.74), systemic
vasculitis (OR 6.23), ulcerative colitis (OR 1.72) and pernicious anaemia (OR 1.57) (Anderson
et al., 2009). This was confirmed in a recent study by Kristinsson et al. that included 9,219
patients with AML and 42,878 matched controls from population-based central registries in
Sweden and reported for a 1.7-fold (95% CI, 1.5–1.9) increased risk of AML (Kristinsson et
al., 2011).
In summary, certain inflammatory medical conditions and a personal history of cancer, in‐
dependent from therapy, are associated with an increased risk of myeloid leukemia. Accord‐
ing to the WHO classification, the distinction of t-AMLs from de novo leukemias is solely
based on the patient’s history but not on the specific biomarkers. Interestingly, it has been
observed that 20–30% of acute leukemias, occurring as second malignancy, developed in the
absence of previous chemo and/or radiotherapy exposure suggesting that besides the pro‐
ven leukemogenic mechanisms of chemo and immunosuppressive therapy and ionizing ra‐
diations, other factors such as genetics, chronic immune stimulation and environment could
favour the onset of multiple neoplastic diseases (Pagano et al., 2001; Johnson et al., 2012). We
have to admit that there is insufficient evidence to label leukemias that develop in patients
who are exposed to cytotoxic agents as ‘therapy-related leukemias’. Further investigation of
the underlying mechanisms and defects, including defects in immunity, DNA repair, and
apoptosis in these patients are warranted rather than studying only drug mechanisms that
lead to leukemogenesis .
3. Risk factors for the development of t-AML
Despite that it has been suggested that chemotherapy (CT) and radiotherapy (RT) are associ‐
ated with a considerable increase in the risk for the development of t-AML compared to the
general population, it still only occurs in a relatively small number of patients. The actuarial
risk varies from study to study, but an increase in the risk of AML of 0.25 to 1 % per year has
been generally observed. The risk is dose dependent and increases exponentially with age
after the age of 40 years, paralleling the risk of primary AML in the general population (Ped‐
ersen-Bjergaard J., 2005).
It is important to identify risk factors that may confer susceptibility to the development of
the condition, including life style, environmental and occupational, as well as host factors,
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such as differences in drug catabolism, membrane transport or inefficient DNA repair that
could explain the predisposition to leukemia. In general chemotherapy confers a greater risk
while involved field radiation is associated with very little or no increased risk of leukemia.
Characteristic features often relate to the type of previous therapy; alkylating agents or RT;
drugs binding to the enzyme DNA-topoisomerase, or antimetabolites.
3.1. Host factors
Lichtman (2007) after a review of 463 618 cases of cancer patients treated with chemotherapy
and radiotherapy, reported 741 cases of AML/MDS, or less than 1%. These data clearly dem‐
onstrate, that after exposure to chemotherapy and/or radiotherapy only a small proportion
of patients develop t-AMLs, which supports the idea, that a host predisposition to the leuke‐
mogenic potential of chemotherapy and radiotherapy probably exits (Czader & Orazi, 2009).
Understanding individual susceptibility factors is important not only to identify patients at
risk in order to tailor therapy, but also to clarify the biological processes leading to leukemo‐
genesis (Leone et al.,2007).
3.1.1. Cancer susceptibility conditions
During the last years, a number of factors were identified, that might cause a predisposition
to both de novo and t-AML, including several cancer susceptibility syndromes (Knoche et
al., 2006). Neurofibromatosis type 1 (NF1) results from a mutation in or deletion of the NF1
gene. The gene product neurofibromin serves as a tumor suppressor; and the decreased pro‐
duction of this protein results in the myriad of clinical features. Children with NF1 are at
increased risk of developing benign and malignant solid tumors as well as hematologic ma‐
lignancies, including acute myelogenous leukemia. The normal NF1 allele is frequently de‐
leted in the bone marrow cells from NF1 patients with hematologic malignancies,
suggesting a pathogenic role in primary leukemogenesis. The idea that NF1 is essential to
regulate the growth of myeloid cells and functions as a tumor suppressor gene raises the
possibility that children with NF1 might be susceptible to the development of secondary
leukemias. (Maris et al.,1997)
Similarly, germline p53 mutations may predispose some children to therapy-related leuke‐
mia and myelodysplasia. Several reports described the occurrence of t-AML in single cases
but no consistent association has been reported to date (Felix et al., 1996; Talwalkar et al.,
2010; reviewed in Sill et al., 2011).
Some observation also suggest that individuals with constitutional genetic variation in the
p53 pathway such as certain allelic variants within the MDM2 and TP53 genes – both in‐
volved in the TP53 DNA damage response pathway – wereat significantly increased risk for
chemotherapy-related AML. Analysis of associations between patients with t-AML and 2
common functional p53-pathway variants, the MDM2 SNP309 and the TP53 codon 72 poly‐
morphism revealed that, an interactive effect was detected such that MDM2 TT TP53
Arg/Arg double homozygotes, and individuals carrying both a MDM2 G allele and a TP53
Pro allele, were at increased risk of t-AML. This interactive effect was observed in patients
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previously treated with chemotherapy but not in patients treated with radiotherapy, and in
patients with loss of chromosomes 5 and/or 7. In addition, there was a trend toward shorter
latency to t-AML in MDM2 GG versus TT homozygotes in females but not in males, and in
younger but not older patients.These data indicate that the MDM2 and TP53 variants inter‐
act to modulate responses to genotoxic therapy and are determinants of risk for t-AML (Ellis
et al., 2008).
The RUNX1/AML1 gene is the most frequent target for chromosomal translocation in leuke‐
mia. Besides, point mutations in the RUNX1 gene are another mode of genetic alteration in
development of leukemia. Monoallelic germline mutations in RUNX1 result in familial pla‐
telet disorder predisposed to acute myelogenous leukemia (Osato M., 2004). Among thera‐
py-related myeloid neoplasms after successful treatment for acute promyelocytic leukemia,
leukaemia transformation of myeloproliferative neoplasms has been reported to have a
strong association with RUNX1 mutations. The mutations occur in a normal, a receptive, or
a disease-committed hematopoietic stem cell (Harada & Harada, 2011).
Recently, an oncogenic germline C-RAF mutations were described in patients with t-AML.
Besides, analysis of blast cells from patients with C-RAF germline mutations revealed loss of
the tumor and metastasis suppressor RAF kinase inhibitor protein (RKIP) as a functional so‐
matic event in carriers of C-RAF germline mutations, which contributes to the development
of t-AML (Zebisch et al., 2009).
Over the last years, genome-wide association studies were also conducted in the attempt to
increase the knowledge of susceptibility factors for t-AML. A recent study of Knight et al.,
2009, represents an important step toward the translational goal of identifying persons at
risk for t-AML at the time of their original cancer diagnosis so that their initial cancer thera‐
py can be modified to minimize this risk. The major findings were that the effect of genetic
factors contributing to cancer risk are potentiated and more readily discernable in t-AML
compared with sporadic cancer. Even in a small sample set, this enrichment allowed for the
identification and replication of likely t-AML–predisposing genetic variants, each of which
may contribute significantly to overall risk. Distinct subsets of patients with t-AML may
have distinct inherited susceptibilities toward t-AML (Knight et al., 2009).
A novel concept addresses epigenetic modifications as an important factor in conferring
disease susceptibility, including global hypomethylation resulting in chromosomal instabili‐
ty and loss of genetic integrity, and promoter specific DNA hypermethylation which leads
to silencing of tumor suppressor genes. Recent studies by Voso et al., 2010 demonstared that
gene promoter methylation is a common finding in t-MDS/AML and has been associated to
a shorter latency period from the treatment of the primary tumor. Among the studied genes,
p15 methylation correlated to monosomy/deletion of chromosome 7q, suggesting that it
could be a relevant event in alkylating agent-induced leukemogenesis.
DAPK1 was more frequently methylated in t-MDS/AML when compared to de novo MDS
and AML (39% vs 15.3% and 24.4%, p=0.0001). Besides, the methylation pattern appeared to
be related to the primary tumor, with DAPK1 more frequently methylated in patients with a
previous lymphoproliferative disease (75% vs 32%, p=0.006). In patients studied for concur‐
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rent methylation of several promoters, t-MDS/AML were significantly more frequently hy‐
permethylated in 2 or more promoter regions than de novo MDS or AML suggesting that
promoter hypermethylation of genes involved in cell cycle control, apoptosis and DNA re‐
pair pathways is a frequent finding in t-MDS/AML and may contribute to secondary leuke‐
mogenesis. These studies support the hypothesis that chemotherapy and individual genetic
predisposition have a role in t-MDS/AML development, and the identification of specific ep‐
igenetic modifications may explain complexity and genomic instability of these diseases and
give the basis for targeted-therapy. The significant association with previous malignancy
subtypes may underlie a likely susceptibility to methylation of specific targets and a role for
constitutional epimutations as predisposing factors for the development of therapy-related
myeloid neoplasm. However, how the epigenetic machinery is disrupted after chemo/radio‐
therapy and during secondary carcinogenesis is still unknown, warranting further studies
(Voso et al., 2010; Greco et al., 2010).
3.1.2. Detoxification pathways
Another probable mechanisms that predispose to t-AML could be related to accumulation of
reactive species that escape detoxification mechanisms or are produced in excess due to
drug metabolizing enzymes polymorphisms, or due to DNA damage which is inefficiently
repaired because of defective DNA-repair (Seedhouse et al., 2004).
Drug or xenobiotic metabolizing enzymes play key roles in the detoxification of xenobiotics,
as well as of a number of commonly used chemotherapeutics. Besides, drug metabolizing
enzymes display a high degree of polymorphism in the general population. The potential
role of the polymorphisms of most of these genes in the etiology of primary or t-AML has
been suggested (Perentesis, 2001).
One of the most important compounds of CYP system is a CYP3A that takes part in the
metabolism of various chemotherapeutics, such as epipodophyllotoxins, etoposide and
teniposide, as well as cyclophosphamide, ifosphamide, vinblastine, and vindesine. It has been
reported that a polymorphism in the 5' promoter region of the CYP3A4 gene (CYP3A4-V) may
decrease production of a precursor of the potentially DNA-damaging quinone (Felix et al.,
1998), therefore the variant gene showed a protective effect against the development of t-AML
(Rund et al., 2005). In contrast, individuals with the CYP3A4-wild type genotype are at
increased risk for t-AML. Often, polymorphic variants in detoxification enzymes may co-
operate in modulating the individual's risk of AML. The absence of polymorphism variants
CYP1A1*2A, del{GSTT1} and NQO1*2 is associated with a 18-fold lower risk of t-AML, whereas
the presence of only NQO1*2 or all three polymorphisms enhances the risk of t-AML (Bolufer
et al., 2007).
Glutathione S-transferases (GSTs) detoxify potentially mutagenic and DNA-toxic metabolites
of several chemotherapeutic agents, such as adriamycin, BCNU, bleomycin, chlorambucil,
cisplatin, etoposide, melphalan, mitomycin C, mitoxantrone, vincristine, cyclophosphamide,
etc. The variant allele of GSTP1 gene, with a substitution of isoleucine to valine at amino acid
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codon 105, is associated with a decreased activity of the enzyme and is over-represented in t-
AML cases compared with de novo AML, particularly among those with prior exposure to
known GSTP1 substrates, but not among patients exposed to radiotherapy alone (Allan et al.,
2001).
An increased risk of developing t-AML has been observed in breast cancer patients with a
677T/1298A haplotype in MTHFR, the gene encoding methylene tetrahydrofolate reductase
involved in methotrexate metabolism, as well as in patients with 677C/1298C haplotype treated
for a primary hematopoietic malignancy with a cyclophosphamide-including regimes
(Guillem et al., 2007).
3.1.3. DNA repair
Another mechanism implicated into the t-AML development includes defects of the individual
DNA-repair machinery which is genetically determined and is believed to be the result of
combinations of multiple genes, each of which may display subtle differences in their activities.
Double-strand breaks in DNA lead either to cell death or loss of genetic material resulting in
chromosomal aberrations. Insufficient repair results in acquisition and persistence of muta‐
tions, whereas elevated levels of repair can inhibit the apoptotic pathway and enable a cell
with damaged DNA, attempting repair, to misrepair and survive (Leone et al., 2007).
There is accumulating evidence suggesting a role for mismatch repair (MMR) in susceptibility
to t-AML. MMR is functionally reflected as microsatellite instability which has been reported
in a significant number of t-AML patient presentation samples (reviewed in Seedhouse et al,
2007). However, double strand breaks (DSBs) in DNA are arguably the most important class
of DNA damage because they may lead to either cell death or loss of genetic material, resulting
in chromosome aberrations. High levels of DSBs arise following ionising irradiation and
chemotherapy drug exposure. Therefore, DSB repair seems to be critical for t-AML suscepti‐
bility. The RAD51 gene plays a key role in DNA-repair process and its variant RAD51-G135C
is associated with a 2.66-fold increased risk of t-AML compared to a control group (Jawad et
al., 2006). If variants of more than one DNA-repair genes are present, for example RAD51-135C
and XRCC3-241Met, the risk of t-AML development is even higher (OR 8.11), presumably
because of the large genotoxic insult these patients receive after their exposure to radiotherapy
or chemotherapy (Seedhouse et al., 2004). Interestingly, it seems that polymorphic variants in
DNA-repair and detoxification enzymes may co-operate, thus having a synergistic effect that
leads to modulation of the individual's risk of AML.The risk of development of AML is further
increased (OR 15.26) in patients in which the burden of DNA damage is increased when a
deletion of the GSTM1 gene is present (Seedhouse et al., 2004). Similarly, carriers of both the
RAD51-G135C and CYP3A4-A-290G variants are at highest AML risk (Voso et al., 2007).
Besides, the genetic interaction between an increased DNA repair capacity in patients with
RAD51-G135C, associated with suppressed apoptosis, and affected stem cell numbers due to
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a HLX1-homeobox gene polymorphism, may increase the number of genomes at risk during
cancer therapy and results in an increased risk of t-AML up to 9.5-fold (Jawad et al., 2006).
Another possible mechanisms might involve the base excision repair (BER) pathway,
which corrects individually damaged bases, occuring as the result of endogenous processes,
ionising irradiation and exogenous xenobiotic exposure; and the nucleotide excision repair
(NER) that removes structurally unrelated bulky damage induced by ultra violet radiation,
environmental factors and endogenous processes and repairs a significant amount of DNA
damage caused by chemotherapeutic agents. A few studies addressed the possible role of
polymorphisms of DNA repair genes encoding the X-ray cross-complementing group 1
(XRCC1) protein which plays an important role in excision and ligation of oxidized DNA
bases and strand breaks, in cooperation with other enzymes in the base excision repair
(BER) pathway, as well as NER polymorphisms, particularly ERCC2 (XPD) Lys751Gln SNP.
Polymorphisms of these genes are associated with decreased DNA repair rates and in‐
creased genotoxic damage, measured by single-strand breaks and chromosomal aberrations.
It might be speculated that compromised repair activity may lead to accumulation of DNA
damage and predispose to secondary cancers and increased treatment-related toxicity to
normal tissues. There is a large set of data implying the functional importance of the
XRCC1-399 polymorphism with the variant Gln allele being associated with a decreased ca‐
pacity to repair DNA damage and a consequent increased level of DNA damage (reviewed
in Seedhouse & Russel, 2007). Evidence has been provided that the variant glutamine allele
of XPD Lys751Gln SNP has been associated with an increased risk of t-AML (Kuptsova-
Clarkson et al., 2010). Interestingly, Seedhouse et al., 2002 demonstrated that the presence of
variant XRCC1-399Gln was protective for t-AML hypothesising that when haematopoietic
progenitor cells in the bone marrow are damaged by therapy, cells with the XRCC1-399Gln
allele (reduced BER capacity) are likely to be driven towards apoptosis, whilst those wild
type cells are more likely to attempt repair, harbour mutations and initiate clonal disease re‐
sulting in t-AML (Seedhouse et al., 2002).
3.2. Previous therapy
By definition t-AMLs occur as late complications of cytotoxic chemotherapy and/or radia‐
tion therapy administered for a prior neoplastic or non-neoplastic disorder (Vardiman et al.,
2008). Chemotherapy and ionizing radiation cause extensive DNA damage and affect un‐
fortunately not only neoplastic but also normal cells. Presumably if genes controlling
growth and differentiation of haematopoietic stem cells are affected, a neoplastic myeloid
clone may arise. Further, repeated therapies may facilitate the selection of such a clone due
to the inevitable immunosupression.
Mechanism of action Agent References
Alkylating agents
Busulfan Dastugue et al., 1990
Carboplatin Miyata et al., 1996
Carmustine Perry et al., 1998
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Mechanism of action Agent References
Chlorambucil Rosenthal et al., 1996
Cisplatin Samanta et al., 2009
Cyclophosphamide Au et al., 2003
Dacarbazine Collins et al., 2009
Dihydroxybusulfan Pedersen-Bjergaard et al.,1980
Lomustine Perry et al., 1998
Mechlorethamine Metayer et al., 2003
Melphalan Kyle et al., 1070; Yang et al., 2012
Mitolactol Bennett et al., 1994
Mitomycin C Nakamori et al., 2003
Procarbazine Travis et al., 1994
Semustine Boice et al., 1983
Temozolomide Noronha et al., 2006
Topoisomerase II
inhibitors
4-Epidoxorubicin Riggi et al., 1993
Bimolane Xue et al., 1997
Dactinomycin Scaradavou et al., 1995
Daunorubicin Blanco et al., 2001
Doxorubicin Yonal et al., 2012
Etoposide Haupt et al., 1994
Mitoxantrone Colovic et al., 2012
Razoxane Bhavnani et al., 1994
Teniposide Ezoe et al. 2012
Antimetabolites
5-fluorouracil Turker et al., 1999
Fludarabine Smith et al., 2011
6-Mercaptopurine Bo et al., 1999
Methotrexate Kolte et al., 2001
Antimicrotubule agents
Docetaxel Griesinger et al., 2004
Paclitaxel See et al., 2006
Vinblastine - leukemogenic effects were not confirmed Carli et al., 2000
Vincristine - leukemogenic effects were not confirmed Carli et al. 2000
Growth factors
Granulocyte colony-stimulating factor Relling et al., 2003
Granulocyte-macrophage colony-stimulating factor Hershman et al., 2007
Immunomodulators Azathioprine Kwong et al.,2010
Table 2. Cytotoxic agents implicated in t-AML.
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Although increased risk of t-AML has been observed after chemotherapy or radiotherapy
alone or in combination, chemotherapy generally confers greater risk. Radiation alone is
rarely associated with increased risk of t-AML. However, cytotoxic drugs are often given in
complex schedules and sometimes in combination with radiotherapy, making it difficult to
assess the tumorigenic role of each drug. The most common cytotoxic drugs commonly im‐
plicated are listed in the Table 2.
3.2.1. Alkylating agents
Alkylaing agents were the first chemotherapeutics to be associated with secondary leukae‐
mia development after successful treatment of other solid or haematopoietic neoplasms
(Kyle et al., 1970; Smit & Meyler, 1970). The mechanisms of DNA damage include either
methylation or DNA inter-stand crosslinking formation. Monofunctional alkylating agents
(incl. dacarbasine, procarbasine, temozolomide) have one reactive moiety and generally in‐
duce base lesions by transferring alkyl groups (-CH3 or CH2-CH3) to oxygen or nitrogen
atoms of DNA bases, resulting in highly mutagenic DNA base lesions (reviewed in Drablos
et al., 2004). In contrast, bifunctional alkylating agents (incl. melphalan, cylophosphamide,
chlorambucil) have two reactive sites and in addition to DNA base lesions, intra- and inter‐
strand crosslinks can be formed by attacking two bases within the same or on opposing
DNA strands which furtheron could result in translocations, inversions, insertions and loss
of heterozygosity (reviewed in Helleday et al., 2008).
The latency between treatment and t-MN is generally long, between 5 and 7 years, and overt
leukemia is frequently preceeded by a dysplastic phase. These cases are generally character‐
ized by loss or deletion of chromosome 5 and/or 7 [-5/del(5q), -7/del(7q)]. In the University
of Chicago's series of 386 patients with t-MDS/t-AML, 79 patients (20%) had abnormalities
of chromosome 5, 95 patients (25%) had abnormalities of chromosome 7, and 85 patients
(22%) had abnormalities of both chromosomes 5 and 7. t-MDS/t-AML with a -5/del(5q) is as‐
sociated with a complex karyotype, characterized by trisomy 8, as well as loss of 12p, 13q,
16q22, 17p (TP53 locus), chromosome 18, and 20q. In addition, this subtype of t-AML is
characterized by a unique expression profile (higher expression of genes) involved in cell cy‐
cle control (CCNA2, CCNE2, CDC2), checkpoints (BUB1), or growth (MYC), loss of expres‐
sion of IRF8, and overexpression of FHL2. Haploinsufficiency of the RPS14, EGR1, APC,
NPM1, and CTNNA1 genes on 5q has been implicated in the pathogenesis of MDS/AML
(Qian et al., 2010). Cases with−7/7q−, but normal chromosome 5 often have methylation of
the CDKN4B gene promoter and somatic mutations of the RUNX1 gene (Christiansen et al.,
2004). Thus, two major patterns of t-AML after alkylating agents have been identified (Ped‐
ersen-Bjergaard et al., 2006).
3.2.2. Topoisomerase II inhibitors
Commonly used topoisomerase inhibitors bind to the enzyme/DNA complex at the strand
cleavage stage of the topoisomerase reaction, interacting with topoisomerase I (topotecan) or
II(doxorubicin, epipodophyllotoxin, e.g. etoposide and teniposide). Topoisomerase II inhibi‐
tors block the enzymatic reaction through religation and enzyme release, leaving the DNA
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with a permanent strand break. Chromosomal breakpoints have been found to be preferen‐
tial sites of topoisomerase II cleavage, which are believed to be repaired by the nonhomolo‐
gous end-joining DNA repair pathway to generate chimaeric oncoproteins that underlie the
resultant leukaemias (reviewed in Joannides & Grimwade, 2010).
T-AMLs occur after a shorter latency time, ranging between 1 and 3 years from the primary
treatment, usually arising without a previous dysplastic phase. Several factors, such as the
schedule and the concurrent use of asparaginase, dexrazoxane or G-CSF, are considered
very important in determining the relative risk. Exposure to topoisomerase II inhibitors is
predominantly associated with t-AML characterized by reciprocal translocations with as
many as 40 different partner genes, such as t(9;11), t(19;11) or t(4;11) in 80% of the cases, as
well as with internal duplications, deletions, and inversions translocations of the MLL gene
on chromosome band 11q23 Other less frequent genetic alterations are t(8;21), t(3;21),
t(16;21), t(17;21), inv(16), t(8;16), t(9;22), t(15;17) (Cowell et al., 2012; Salas et al., 2011, Yin et
al., 2005; Felix, 1998).
3.2.3. Antimetabolites
Antimetabolites (e.g. azathioprine, 6-thioguanine, fludarabine) share structural similarities
with nucleotides, and can be incorporated into DNA or RNA, thereby interfering with repli‐
cation and causing inhibition of cell proliferation. Once placed in the newly synthesized
DNA strand, metabolites are prone to methylation and formation of the highly mutagenic
base lesions that closely resemble the induced by alkylating agents. Cell cycle arrest and cell
death after treatment are triggered by the DNA MMR machinery. However, MMR-deficient
cells can tolerate methylated lesions, potentially forming a leukaemic clone (Offman et al.,
2004). In line with the cytogenetic aberrations found with alkylating agents, patients with t-
AML after antimetabolites treatment frequently harbour partial or complete loss of chromo‐
somes 5 and 7 (Morrison et al., 2002; Smith et al., 2011).
3.2.4. Granulocyte-colony stimulating factor (G-CSF)
Since some of G-CSF effects include stimulation of the proliferation of granulocytic progeni‐
tors and premature release of neutrophils from the bone marrow enhancing their capacity
for phagocytosis, ROS (reactive oxygen species) generation and bacterial cell killing, two
mechanisms have been implicated in the G-CSF-mediated promotion of therapy-related
myeloid neoplasms (Beekman & Touw, 2010). First, G-CSF-induced production and release
of ROS by bone marrow neutrophils may result in increased DNA damage and mutation
rates in Human hematopoietic stem and progenitor cells (Touw & Bontenbal, 2007). Second,
repeated application of G-CSF results in a continuous leaving of these cells from their pro‐
tective bone marrow niche, which may render them more susceptible to genotoxic stress
(Trumpp et al., 2010). In an attempt to evaluate the risk of acute myeloid leukemia or myelo‐
dysplastic syndrome in patients receiving chemotherapy with or without G-CSF, Lyman et
al., 2010 systematically reviewed 25 randomized controlled trials and identified 6058 and
6746 patients were randomly assigned to receive chemotherapy with and without initial G-
CSF support, respectively. An absolute risk of 0.43% was determined, however, the adminis‐
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tration of G-CSF showed benefits for a substantial proportion of patients and outweighs the
increased risk of secondary leukemias.
3.2.5. Ionizing radiation
The risk of leukemia following radiation is considerably smaller than after chemotherapy,
with a relative peak at the 5th to 9th year after radiotherapy exposure showing a slow de‐
cline afterwards. The underlying mechanisms refer to the formation of reactive oxygen spe‐
cies through radiolysis of water molecules resulting from the exposure of cells to ionizing
radiation, which are highly reactive and capable of oxidizing or deaminating DNA bases
and increasing the frequency of DNA double strand breaks (Rassool et al., 2007), on one
hand, or can also directly induce strand breaks by disruption of the sugar phosphate back‐
bone of DNA, potentially leading to the formation of large scale chromosomal rearrange‐
ments (Klymenko et al., 2005). The radiation-related leukemia risk depends on the dose
given to the active bone marrow, the dose rate, and the extent of exposed marrow (Travis L.,
2006). Due to cell killing at higher doses the risk of t-AML is considerably larger at low
doses: patients in whom high radiation doses to limited fields have been given are associat‐
ed with little or no increased risk of leukemia (UNSCEAR 2000 Report), while exposure of
extended fields of radiotherapy as well as low-dose total body irradiation may result in con‐
siderably higher risks (Travis et al., 1996; Travis et al., 2000) of leukemia.
4. Molecular pathogenesis
It has been suggested, that t-AML are a direct consequence of mutational events induced by
chemotherapy, radiation therapy, immunosuppressive therapy, or a combination of these
modalities (Godley & Larson, 2008). Similarly to de novo AML, t-AMLs are complex genetic
diseases, requiring cooperating mutations in interacting pathways for disease initiation and
progression. Establishing a leukaemic phenotype requires acquisition of crucial genetic aber‐
rations, such as point mutations, fusion genes formation or gene rearrangements, deletion or
inactivation of tumor-suppressor genes, or changes in the expression of critical oncogenes or
growth factor receptor genes (Larson, 2004). Most probably, multiple events are involved in
which DNA damage from exposure to genotoxic stress leads to the secondary abnormalities
that cause t-AML (Pedersen-Bjergaard, 2001). A major difference between t-AML and de no‐
vo AML is that high doses of mutagenic chemo-/radiotherapy impact on the DNA of haema‐
topoietic stem and precursor cells in the socondary myeloid neoplasms. In contrast, chronic
exposure to low doses of occupational/environmental agents over extended periods of time
may be operational in the development of high-risk de novo MDS/AML (Sill et al., 2011).
However, these differences are not apparent in all cases and there is a clinical and biological
overlap between t-AML and high-risk de novo myelodysplastic syndromes and acute mye‐
loid leukaemia suggesting similar mechanisms of leukaemogenesis. Recently, similarities in
therapy-related and elderly acute myeloid leukemia were found in terms of the similar clini‐
cal and molecular aspects and unfavorable prognosis. In older individuals prolonged expo‐
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sure to environmental carcinogens may be the basis for these similarities (D'Alò et al., 2011).
On the other hand, a recently published study reported that AML diagnosed in the past dec‐
ade in patients after receiving radiotherapy alone differ from therapy-related myeloid neo‐
plasms occurring after cytotoxic chemotherapy/combined-modality therapy and share
genetic features and clinical behavior with de novo AML/MDS, suggesting that post-radio‐
therapy MDS/AML may not represent a direct consequence of radiation toxicity (Nardi et
al., 2012). Therefore, other factors might be involved such as genetic variants conferring pre‐
disposition to the primary malignacy that may also be of relevance for therapy-related leu‐
kaemogenesis and account for subtle biologic differences between t-MNs and high-risk de
novo MDS/AML (Sill et al., 2011). Besides, the nature of the causative agent has an impor‐
tant bearing upon the characteristics, biology, time to onset and prognosis of the resultant
leukaemia (Joannides & Grimwade, 2010).
Various pathogenetic mechanisms have been elucidated so far and different genetic path‐
ways for the multistep development of t-MDS/t-AML have been proposed, in which particu‐
lar mechanisms of DNA damage that lead either to chromosomal deletions, balanced
translocations or induction of defective DNA-mismatch repair could promote survival of
misrepaired cells giving rise to the leukemic clone (Leone at al., 2007). Multiple tumor sup‐
pressor genes or oncogenes may need to be mutated to ultimately transform a cell resulting
in impaired differentiation of hematopoietic cells and/or in proliferative and survival ad‐
vantage. Different molecular pathways may cooperate in the genesis of leukemia and at
least 8 alternative genetic pathways have been defined based on characteristic recurrent
chromosome abnormalities(Pedersen-Bjergaard et al., 2007).
Interestingly, analysis of gene expression in CD34+ cells from patients who developed t-
MDS/AML after autologous hematopoietic cell transplantation revealed altered gene expres‐
sion related to mitochondrial function, metabolism, and hematopoietic regulation and the
genetic programs associated with t-MDS/AML are perturbed long before disease onset (Li et
al., 2011). Similarly, the gene expression profiles in diagnostic acute lymphoblastic leukemic
cells from children treated on protocols that included leukemogenic agents, revealed a sig‐
nature of 68 probes, corresponding to 63 genes, that was significantly related to risk of t-
AML. The distinguishing genes included transcription-related oncogenes (v-Myb, Pax-5),
cyclins (CCNG1, CCNG2 and CCND1) and histone HIST1H4C. Common transcription factor
recognition elements among similarly up- or downregulated genes included several in‐
volved in hematopoietic differentiation or leukemogenesis (MAZ, PU.1, ARNT). This ap‐
proach has identified several genes whose expression distinguishes patients at risk of t-
AML, and suggests targets for assessing germline predisposition to leukemogenesis (Bogni
et al., 2006).
The comparison of samples from t-AML and de novo AML patients using high resolution
array CGH revealed more copy number abnormalities (CNA) in t-AML than in de novo
AML cases: 104 CNAs with 63 losses and 41 gains (mean number 3.46 per case) in t-AML,
while in de novo-AML, 69 CNAs with 32 losses and 37 gains (mean number of 1.9 per case).
The authors suggested that CNA can be classified into several categories: abnormalities
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common to all AML; those more frequently found in t-AML and those specifically found in
de novo AML (Itzhar et al., 2011).
Recently, a growing amount of data suggests that DNA methylation abnormalities may con‐
tribute to a multistep secondary leukemogenesis. Two distinct alterations of normal DNA
methylation patterns may occur in cancer: (i) a global hypomethylation resulting in chromo‐
somal instability and loss of genetic integrity, and (ii) promoter specific DNA hypermethyla‐
tion which leads to silencing of tumor suppressor genes. Cytotoxic drugs and radiation have
been shown to affect tissue DNA methylation profile. Radiation is able to induce a stable
DNA hypomethylation in both target and bystander tissues. Gene promoter methylation is a
common finding in t-MDS/AML and has been associated to a shorter latency period from
the treatment of the primary tumor. Among the studied genes, p15 methylation correlated to
monosomy/deletion of chromosome 7q, suggesting that it could be a relevant event in alky‐
lating agent-induced leukemogenesis. Besides, a frequent methylation of DAPK in the t-
MDS/AML group was observed, especially in patients with a previous lymphoproliferative
disease. In patients studied for concurrent methylation of several promoters, t-MDS/AML
were significantly more frequently hypermethylated in 2 or more promoter regions than de
novo MDS or AML suggesting that promoter hypermethylation of genes involved in cell cy‐
cle control, apoptosis and DNA repair pathways is a frequent finding in t-MDS/AML and
may contribute to secondary leukemogenesis. However, how the epigenetic machinery is
disrupted after chemo/radiotherapy and during secondary carcinogenesis is still unknown
(Voso et al., 2010).
5. Clinical features
Similarly to de novo AML, therapy-related AMLs comprise an extremely heterogeneous
group of biologically different hematologic malignancies and their clinical presentation var‐
ies in a significant degree from cases to case, depending on applied chemo- and or radio‐
therapy for the primary disorder as well as on other factors.
As expected, the most frequent complaints at the presentation of patients with t-AMLs in‐
clude: fatigue, weakness, and occasionally fever, bleeding complications caused by throm‐
bocytopenia, anemia, and leukopenia. Features that are fairly common in de novo acute
leukemia, such as hepatomegaly, splenomegaly, lymphadenopathy, gingival hyperplasia,
skin rash, or neurological complications, are notably absent from the presentations of pa‐
tients with t-MDS/t-AML. Bone marrow biopsies typically reveal hypercellularity with some
degree of marrow fibrosis, although hypocellular and even aplastic marrows can be seen
(Godley & Le Beau, 2007).
Morphologically, t-AML can present in the broad spectrum of myeloid leukemias. Mostly in
patients after previous therapy with alkylating agents multilineage dysplasia can be ob‐
served. However, dysplasia can be seen in some patients with balanced translocations as
well. Dysgranulopoiesis includes hypogranular neutrophils, with hypo- or hyperlobulated
nuclei, nuclear excrescences, and pseudo-Pelger-Huet nuclei. Red cell morphology in most
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cases is characterised by macrocytosis and poikilocytosis, periodic acid-Schiff-positive nor‐
moblasts, dyserythropoiesis with megaloblastoid changes, erythroid hyperplasia, ringed
sideroblasts, nuclear budding, karyorrhexis, binuclearity, and nuclear bridging. Megakaryo‐
cyte dysplasia within the bone marrow includes micromegakaryocytes, abnormal nuclear
spacings, mononuclear forms, giant compound granules, and hypogranular cytoplasm. Cas‐
es of therapy-related myeloid neoplasms related to treatment with topoisomerase II inhibi‐
tors typically present as overt acute myeloid leukemia without a myelodysplastic prephase.
Morphologic features are not unique in therapy-related cases. Although monocytic and
monoblastic differentiation is often present, the appearance may be that of de novo cases,
including those with recurrent cytogenetic abnormalities (Godley & Le Beau, 2007; Vardi‐
man et al., 2008).
Immunophenotypic studies are not used to distinguish t-AML from de novo cases but rath‐
er to clarify abnormal populations, reflecting the heterogeinety of the underlying morpholo‐
gy. The phenotype findings are similar to their de novo counterparts. The myeloblasts are
characteristically CD34-positive and express pan-myeloid markers (CD13, CD33) and flow
cytometry may be helpful in assessing the proportion of myeloid blasts, as well as aberrant
antigenic expression, such as CD7, CD56, CD19, etc. Immunophenotypic maturation pat‐
terns of the myeloid and erythroid lineages may also be evaluated. The maturing myeloid
cells may show abnormal patterns of antigen expression and/or light scatter properties.
However, the relevance of such findings is similar to that in de novo cases (Wood B., 2007;
Vardiman et al., 2008).
Clinical and laboratory features of patients with t-AML with recurrent genetic abnormalities
have been of particular interest. In some studies, hematologic characteristics of patients with
t-AML with t(8;21) and inv(16), are identical to those of de novo AML with the same karyo‐
types (Quesnel et al., 1993). Simmilarly, according to Duffield et al., 2012, t-APL and de novo
APL had abnormal promyelocytes with similar morphologic and immunophenotypic fea‐
tures, comparable cytogenetic findings, and comparable rates of FMS-like tyrosine kinase
mutations (Duffield et al., 2012). Interestingly, compared with patients with t-APL, those
with de novo APL had a greater median body mass index-BMI (31.33 vs. 28.48), incidence of
obesity (60.4% vs. 27.3%), and history of hyperlipidemia (45.3% vs. 18.2%), suggesting that
abnormalities in lipid homeostasis may in some way be of pathogenic importance in de no‐
vo APL (Elliott et al., 2012). t-AML-t(8;21) shares many features with de novo AML-t(8;21)
(q22;q22), however patients with t-AML-t(8;21) are older and had a lower WBC count, sub‐
stantial morphologic dysplasia, Auer rods are detected only certain patients, an increase in
eosinophils is uncommon (Gustafson et al., 2009). The detection of morphologic features
characteristic of t(8;21) with associated multilineage dysplasia is fairly unique to t(8;21) t-
AML/MDS (Arber et al., 2002). Despite that, some studies reported that t-AML/MDS with
t(8;21) may have a high frequency of expression of CD19 and CD34 (Arber et al., 2002), this
was not confirmed by others (Gustafson et al., 2009).
Rearrangements involving the MLL gene on chromosome band 11q23 are a hallmark of ther‐
apy-related acute myeloid leukemias following treatment with topoisomerase II poisons (Li‐
bura et al., 2005). French-American-British (FAB) subtype distribution of cases with
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11q23/MLL rearrangement does not differ between de novo AML and t-AML (Schoch et al.,
2003). In adults, patients with t-AML and t(9;11)(p21-22;q23) are more likely to be women
and older, without other statistically significant differences with regard to clinical features;
immunophenotype; morphologic, cytogenetic, and molecular genetic features; or miRNA
expression, compared to de novo AML cases (Chandra et al., 2010). Pediatric patients with
t(9;11) positive secondary AML are older at diagnosis, have higher hemoglobin levels, and
central nervous system leukemia or hepatosplenomegaly is less frequent. Whereas the
t(9;11)(p21;q23) occurred exclusively in the FAB M5 subtype in de novo AML, the FAB M0
and M4 subtypes were also represented in secondary cases (Sandoval et al., 1992).
Chromosome/ Molecular
Aabnormality
GIMEMA
2001
n=127
G-A AML SG
2011
n=200
Serbia
2012
n=42
Our data
2012
n=26
De novo AML,
2011
n= 2653
Age – mean (range) years 58
(21-87)
57.8
(18.6-79.4)
56.07
(23-84)
53.5
(22-83)
53.2
(16.2-85)
Male %/female % 44/56 32/68 29/71 46/54 53/47
Latency median (range)
months
52
(2-379)
48.5
(4-530)
54.62
(6-243)
48
(3-216)
NA
WBC – mean x109/L 6.7 7.4 27.2 24.4 12.5
CR rate % 55 63 23.8 42 67
Median OS months 7 12 5.94 6 20
Reference Pagano et al,
2001
Kayser et al,
2011
Suvajdžić et al,
2012
Balatzenko et al.,
2012
Kayser et al, 2011
Table 3. Major clinical data in t-AML patients’ cohorts.
The analysis of 179 t-AML patients from the GIMEMA Archive of Adult Acute Leukaemia,
including 41 treated with surgery only, allowed for the distinction of some differences com‐
pared to de novo AML cases. The median age of t-AML was significantly higher than that of
other AML (63 years vs. 57 years), the number of men was significantly lower than the num‐
ber of women [4.8% vs. 7.4%) most probably due to the high incidence in breast cancer pa‐
tients; as was the number of patients aged <65 years [5.3% vs. 7.5%]. Interestingly, an
increased incidence of cancer was observed among first-degree relatives of patients with
AML occurring after a primary malignancy [36.9% vs. 27.2% in de novo AML]. Prevalent
types of primary malignancies were breast cancer, lymphoma and Hodgkin's disease (Paga‐
no et al., 2001). Higher WBC count and females predominance in t-AML had also been ob‐
served by others (Schoch et al., 2004).
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6. Genetic and molecular features
It is widely accepted, that the spectrum of chromosome aberrations is comparable in t-AML
and de novo AML, however the frequencies of distinct cytogenetic categories is different de‐
pending on the characteristics of the analyzed patient cohort (reviewed in Schoch et al.,
2004). Two are the most striking features of t-AML: the extremely high frequency of abnor‐
mal clonal karyotype up to 75%-96% compared to 50%-59% in de novo AML (Schoch et al.,
2004; Godley & Larson, 2008; Grimwade et al., 2010; Mauritzson et al., 2002); and a clear pre‐
dominance of unfavorable cytogenetics, such as deletion or loss of chromosomes 5 and/or 7
or a complex karyotype (Godley & Larson, 2008). However, the frequency and the spectrum
of abnormal karyotypes varies depending on the nature of the applied antecedent anti-neo‐
plastic therapy (Rund et al., 2004).
Unbalanced chromosome aberrations such as abnormalities of chromosomes 5 and/or 7 ac‐
count for 76% of the cases with an abnormal karyotype.Complex karyotypes are seen in
26.9% of t-AML as compared to 11.30% of de novo AML (Schoch et al., 2004). Recurring bal‐
anced rearrangements account for 11% of cases (Larson & Le Beau, 2005), with a specific
over-presentation of 11q23 abnormalities – 12.9% vs. 3.7% in de novo AML (Schoch et al.,
2004). Comparative data on chromosome/molecular aberrations in t-AML and de novo AML
are presented in Table 4.
6.1. Unbalanced chromosome aberrations
Generally, t-AMLs with unbalanced chromosome abnormalities are developed after expo‐
sure to alkylating agents and/or ionizing radiation. This group is considered as a biological‐
ly distinct form and the most frequent type of t-AML accounting for approximately 75% of
cases. The disease usually follows a long period of latency generally occuring 5–10 years af‐
ter the drug exposure and is characterized frequently by a preleukemic phase and tri-lineage
dysplasia. Typical cytogenetical aberrations comprise loss or deletion of chromosome 5
and/or 7 [-5/del(5q), -7/del(7q)]. Frequently, abnormalities of chromosome 5 are part of a
complex karyotype, that additionally includes trisomy 8, as well as loss of 12p, 13q, 16q22,
17p (TP53 locus), chromosome 18, and 20q (Qian et al., 2010).
The complex and hypodiploid karyotypes with unbalanced chromosome changes results in
multiple severe molecular abnormalities with a gene-dosage effect for some of the genes that
depend on the nature of the primary chromosome aberration. The loss of the coding regions
for tumor suppressor genes from hematopoietic progenitor cells is a particularly unfavora‐
ble event, since the remaining allele becomes susceptible to inactivating mutations leading
to the leukemic transformation (Leone et al., 2001; Joannides & Grimwade, 2011).
Interestingly, significant proportion of older patients are diagnosed with leukaemia with no
antecedent history of exposure, and some of these cases show a remarkably similar pheno‐
type to classic therapy-related leukaemia (D'Alò et al., 2011). The specific cytogenetic abnor‐
malities common to MDS, alkylating-agent-related AML and poor-prognosis AML [3q-,
-5/5q-, -7/7q-, +8, +9, 11q-, 12p-, -18, -19, 20q-, +21, t(1;7), t(2;11)], probably reflect a common
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pathogenesis distinct from that of other de novo AMLs. Possibly, tumour suppressor genes
are implicated and genomic instability may be a cause of multiple unbalanced chromosomal
translocations or deletions. Typically, these patients are either elderly or have a history of
exposure to alkylating agents or environmental exposure 5-7 years prior to diagnosis (Dann
& Rowe, 2001).
Chromosome/Molecular Aabnormality De novo AML Therapy-related AML
BRAF 1.5% 6%
CEBPA mutations 7% - 15% 0 – 6%
c-KIT mutations 2% - 5% 1% - 4%
DNMT3A mutations 18% - 22% 16%
FLT3internal tandem duplications 22% - 35% 7% - 12%
FLT3 – tyrosine kinase domain mutations 5% - 8% 2% - 2.5%
IDH1/IDH2 mutations 17% - 33% 3% -12%
Inv(16)/t(16;16) / CBFβ-MYH11 4% - 6% 1% - 8%
Inv(3)/t(3;3) / EVI1 1% - 2% 0.2% - 1%
JAK2 mutations Rare Rare
MLL partial tandem duplications 6% 2% - 4%
NPM1 mutations 19% - 35% 12% - 16%
NRAS mutations 6% - 10% 11% - 12%
PTPN11 mutations 3% - 5% 4.%
RUNX1 mutations 5% - 10% 4% - 9%
t(15;17) / PML-RARα 4% - 11% 2% - 3%
t(8;21) / RUNX1-ETO 5% - 9% 2% - 5%
t(9;11) / MLLT3-MLL 1% - 2% 6% - 11%
t(v;11)(v;q23) / MLL rearrangements 2% - 4% 4% - 12%
TET2 mutations 8% - 13% 9%
TP53 mutations 10-15% 18% - 25%
WT1 mutations 4% - 7% 17%
References: Abbas et al., 2010; Ahmad et al., 2009; Bacher et al., 2011; Bacher et al., 2007; Christiansen et al., 2005;
Christiansen et al., 2004; Christiansen et al.,2007; Fried et al., 2012; Gaidzik et al., 2011; Green et al., 2010; Kayser et al.,
2011; Kosmider et al., 2011; Lee et al., 2004; Lin et al., 2005; Marcucci et al., 2010; Mauritzson et al., 2002; Paschka et
al., 2010; Pedersen-Bjergaard et al., 2008; Preudhomme et al., 2002; Shen et al., 2011; Takahashi et al., 2000; Thiede et
al., 2002; Westman et al., 2011.
Table 4. Chromosome and molecular abnornalities in t-AML compared to de novo AML.
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The critical genetic consequences of unbalanced chromosome aberrations in MDS and AML
have remained unknown (Pedersen-Bjergaard et al., 2007). The genetic consequences of a
deletion may be a reduction in the level of one or more critical gene products (haploinsuffi‐
ciency), or complete loss of function. The latter model, known as the “two-hit model”, pre‐
dicts that loss of function of both alleles of the target gene would occur, in one instance
through a detectable chromosomal loss or deletion and, in the other, as a result of a subtle
inactivating mutation, or other mechanisms, such as transcriptional silencing. However, the
respective genes on the “intact copy” seem to be not affected, since no submicroscopic dele‐
tions or mutations of the remaining allele in any of the genes within the commonly deleted
segment (CDS) were detected (reviewed in Le Beau & Olney, 2009). Therefore, most proba‐
bly loss of only a single copy of a relevant gene (haploinsufficiency) perturbs cell fate. Dele‐
tions of putative tumor suppressor genes at chromosomes 5q and 7q are believed to underlie
the molecular pathogenesis of alkylating agent- related leukemias. Since similar aberrations
occur in de novo MDS/AML, knowledge on potential regions of involvement at chromo‐
somes 5q and 7q derives from de novo and treatment-related cases, but the specific genes in
these regions that are important in leukemia pathogenesis continue to remain elusive (Jerez
et al., 2011).
On chromosome 5q, two CDSs were identified in 5q31.2 (de novo and t-MDS/t-AML) and
5q33.1 (in 5q− syndrome). The 970 kb CDS within 5q31.2 comprises 20 genes that encoded
proteins that take part in regulation of mitosis and G2 checkpoint, transcriptional control,
and translational regulation. The second 1.5 Mb CDS is located within 5q33.1, distal to the
CDS in 5q31.2 and contains 40 genes, 33 of which are expressed within the CD34+ hemato‐
poietic stem/progenitor cell compartment cells and, therefore, represent candidate genes
(Boultwood et al., 2002).The genes that might be involved in leukemogenesis due to gene
dosage effect include RPS14, EGR1, NPM1, APC, and CTNNA1 (reviewed in Qian et al.,
2010).
Monosomy 7 and del(7q) occur in a variety of clinical contexts including de novo MDS and
AML, leukemias associated with a constitutional predisposition, and therapy-related MDS
or AML (Luna-Fineman et al., 1995). Several regions with allelic loss were identified in pa‐
tients with 7q deletions, including entire regions from chromosome 7q22 to 7q31, 7q32-7q35,
etc. (Kratz et al., 2001; Le Beau et al., 1996; Dohner et al.,1998). Besides, case analysis of allel‐
ic loss at 7q31 and 7q22 loci revealed retention of sequences between these loci or submicro‐
scopic allele imbalance for a different distal locus, suggesting that multiple distinct critical
chromosme7q genes are involved in MDS and AML.
Critical genes affected by monosomy 7 and del(7q) are still unknown. Several candidate
genes have been suggested as involved in leukemogenesis. hDMP1 (cyclin D-binding Myb-
like protein) gene, that negatively regulates cell proliferation is considered as possible as a
tumor suppressor in acute leukemias with deletions of the long arm of chromosome 7 (Bod‐
ner et al., 1999). MLL5 is a candidate tumor suppressor gene located within a 2.5-Mb interval
of chromosome band 7q22, that seems to be a key regulator of normal hematopoiesis and
which is frequently deleted in human myeloid malignancies. Since no inactivating muta‐
tions and decreased MLL5 mRNA expression were detected, the most probable mechanism
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of gene inactivation is haploinsufficiency (Heuser et al., 2009; Zhang et al., 2009; Emerling et
al., 2002).
PIK3CG, which encodes the catalytic subunit p110 gamma of phosphoinositide 3-OH-kin‐
ase-gamma (PI3K gamma), has been assigned to the same frequently deleted in myeloid ma‐
lignancies chromosome band 7q22. Although that missense variations affecting residue 859
in the N-terminal catalytic domain of the protein were found, this fact probably represents a
polymorphism and it is unlikely that the gene acts as a recessive TSG in myeloid leukemias
with monosomy 7 (Kratz et al., 2002).
Deletions of chromosome band 17p13 or loss of a whole chromosome 17 harboring the p53
gene were shown to be associated with point mutations of p53. Patients with p53 mutations
characteristically present complex karyotypes and complicated chromosome rearrange‐
ments with duplication or amplification of chromosome bands 11q23 and 21q22 encompass‐
ing the MLL and the AML1 genes, resulting in “sandwich-like” marker chromosomes made
of material from at least three different chromosomes.
Application of multicolor fluorescence in situ hybridization (M-FISH) allows better identifi‐
cation of chromosome abnormalities compared to G-banding. A clustering of breakpoints
was observed in the centromeric or pericentromeric region of chromosomes 1, 5, 7, 13, 17, 21,
and 22 in almost 50% of patients with t-MDS and t-AML and an abnormal karyotype. In
most of the patients with chromosome derivatives containing material from 3 or more chro‐
mosomes or having “sandwich-like” chromosomes, those made up of several small inter‐
changing layers of material from two chromosomes, showed mutations of TP53 (Andersen
et al., 2005).
In some patients treated with alkylating agents an amplification or duplication of AML1
gene (21q22) or MLL gene (11q23) can be found. Generally, no point mutations in AML1
gene or MLL gene rearrangements were seen in these cases. Interestingly, almost all these
patients presented with acquired point mutations of the TP53 gene, which supports the piv‐
otal role of the impaired TP53 function in the development of gene amplification or duplica‐
tion in t-MDS and t-AML (Andersen MK, et al.,2001; Andersen MK, et al. 2005).
6.2. Balanced chromosome aberrations
Balanced chromosome translocations and inversions have been found in 10.6% of t-AML.
These types of aberrations are observed most commonly in patients treated with agents tar‐
geting topoisomerase II. Other typical features of t-AML with balances chromosome abnor‐
malities comprise presentation of the disease as an overt leukemia without a
myelodysplastic phase and a short latency period (6–36 months). The formation of these
chromosome abnormalities is considered as a result of multiple DNA strand breaks follow‐
ing the topoisomerase II inhibitors. Generally, chromosomal breakpoints have been found to
be preferential sites of topoisomerase II cleavage that seems to be repaired by the nonhomol‐
ogous end-joining DNA repair pathway to generate chimaeric oncoproteins that underlie
the resultant leukaemias (Joannides & Grimwade, 2010).
Leukemia122
Most often, chromosome translocations involve chromosome bands 11q23 or 21q22 with re‐
arrangement of the MLL and the AML1 genes, but also less frequently other balanced rear‐
rangements such as the inv(16)(p13q22), and the t(15;17)(q22;q11) (Dissing et al., 1998;
Andersen MK et al.,1998), etc. Translocations are often present as the sole abnormality.
It seems, that an association between the nature of the applied drug and the type of translo‐
cation exists, since translocations involving 11q23 are more frequent after treatment with ep‐
ipodophyllotoxins, whereas translocations affecting 21q22, inv(16), and t(15;17) are more
common after anthracyclines (Andersen et al., 1998). Other less common, recurrent, bal‐
anced cytogenetic abnormalities occurring in myeloid neoplasms associated with previous
therapy include 3q21q26, 11p15, t(9;22)(q34;q11), 12p13, and t(8;16)(p11;p13) (Czader et al.,
2009).
Recently, translocations involving the NUP98 gene on chromosome 11p15.5 have been
cloned from patients with hematological malignancies. To date, at least 8 different chromo‐
somal rearrangements involving NUP98 have been identified. The resultant chimeric tran‐
scripts encode fusion proteins that juxtapose the N-terminal GLFG repeats of NUP98 to the
C-terminus of the partner gene. Of note, several of these translocations have been found in
patients with t-AML, suggesting that genotoxic chemotherapeutic agents may play an im‐
portant role in generating chromosomal rearrangements involving NUP98 (Lam & Aplan,
2001).
Generally, the recurrent balanced chromosome aberrations lead to the formation of fusion
genes, with the participation of hematopoietic transcription factors genes, that encode hi‐
meric oncoproteins playing a crtical role in leukemogenesis.
6.2.1. Translocations involving chromosome 11q23/ MLL gene
MLL  encodes a histone methyltransferase that  play a key role  in the regulation of  gene
expression. In leukemia, this function is subverted due to replacement of the C-terminal
functional domains of MLL with those of a fusion partner, yielding a newly formed chimeric
protein with an altered function that endows hematopoietic progenitors with self-renewing
and leukemogenic activity (Eguchi M, 2005). Although the molecular basis for the oncogenic
activity of MLL chimeric proteins is not completely understood, it seems to be derived, at least
in part, through activation of clustered homeobox (HOX) genes (Harper & Aplan, 2008).
Translocations involving chromosome 11q23, where the MLL gene is located, are typical
aberrations observed in adults with t-AML, where the frequency is significantly higher com‐
pared to de novo AML cases – 9.4% vs. 2.6% (Schoch et al., 2003). Frequent partners are
chromosomes 9, 19 and 4 in the t(9;11), t(19;11) and t(4;11) translocations. Particularly higher
frequency in t-AML was reported in regard to t(9;11), compared to de novo AML - 11% ver‐
sus 1% respectively (Kayser et al., 2011). Besides, some structural differences between de no‐
vo AML and t-AML exist, although their clinical significance is still unclear. Typical
examples of such differences are the t-AML with MLL rearrangements that, similarly to in‐
fant leukemias, have genomic breakpoints in MLL tending to cluster in the 3' portion, in con‐
trast to adults with de novo AML, in whom the breakpoint is located in the 5' portion of the
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8.3 kb breakpoint cluster region (BCR) (Zhang & Rowley,2006). Younger age, a mean period
of latency of 2 years and monocytic subtypes are characteristic features of this type of leu‐
kaemia (Leone et al., 2001).
6.2.2. Translocations involving chromosome 21q22 / AML1 (CBFA2/RUNX1) gene
T-AML with balanced 21q22 aberrations has been associated with prior exposure to radia‐
tion, epipodophyllotoxins, and anthracyclines. Translocations involving chromosome 21q22
comprise multiple abnormalities, presented as t(8;21) (56%), t(3;21) (20%), and t(16;21) (5%)
(Slovak et al., 2002), t(1;21)/RUNX1-PRDM16 (Sakai et al., 2005) and other partner chromo‐
somes (Slovak et al., 2002). The median latency for 21q22 patients is 39 months, compared to
26 months for 11q23 patients, 22 months for inv(16), 69 months for rare recurring aberra‐
tions, and 59 months for Unique (nonrecurring) balanced aberration (Slovak et al., 2002).
6.2.3. Translocations involving chromosome 11p15/ NUP98 gene
The NUP98 gene has been reported to be fused with at least 15 partner genes in leukemias
with 11p15 translocations, including PRRX1 (PMX1), HOXD13, RAP1GDS1, HOXC13,
TOP1, etc. (Kobzev et al., 2004). The resultant chimeric transcripts encode fusion proteins
that juxtapose the N-terminal GLFG repeats of NUP98 to the C-terminus of the partner gene.
Of note, several of these translocations have been found in patients with t-AML, suggesting
that genotoxic chemotherapan important role in generating chromosomal rearrangements
involving NUP98 (Lam & Aplan, 2001).In a survey of childhood t-AML/t-MDS, 11p15 trans‐
locations were found in 6% of the cases, including t(11;17)(p15;q21), t(11;12)(p15;q13), t(7;11)
(p15;p15), inv(11)(p15q22), and add(11)(p15) and it has been suggested that NUP98 may be a
target gene for t-AML/MDS, and that t-AML/MDS with a fusion of NUP98 and HOX or
DDX10 genes may be more frequent in children than in patients of other age groups (Nish‐
iyama et al.,1999).
6.2.4. Translocations associated with “favorable” prognosis
A relatively distinct subgroup of t-AML comprises patients bearing “favorable” cytogenetic
abnormalities, such as inv(16) and t(15;17) (Andersen MK et al. 2002), and more rarely –
t(8;21) (Gustafson et al., 2009). These aberrations have been observed after alkylating agents
and/or topoisomerase II inhibitors. High frequency of t(15;17), inv(16) and t(8;21) (18-29%,
21%, and 15% respectively) has also been reported in patients treated with radiotherapy on‐
ly (Andersen et al., 2002; Yin et al., 2005).
The median latency period after the treatment is 22 months in patients with inv(16), 29
months in patients with t(15;17) and 37 months in patients with t(8;21). More than half of the
cases in each group had additional cytogenetic abnormalities. Trisomy of chromosomes 8,
21, 22 and del(7q) are the most frequent additional abnormalities in the inv(16) subgroup,
whereas trisomy 8, monosomy 5, and del(16q) are most frequent in the t(15;17) subgroup.
Additional abnormalities commonly associated with t(8;21) include loss of a sex chromo‐
some and Trisomy 4 (Andersen et al., 2002; Gustafson et al., 2009; Yin et al., 2005).
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Interestingly, some structural differences were observed between patients positive for these
aberrations with de novo AML and t-AML.In t-AML with inv(16)/t(16;16), the unusual rare
types of fusion CBFB-MYH11 transcripts were found to be significantly more frequent com‐
pared to de novo AML (Schnittger et al., 2007).
In therapy related t(15;17) APL, a prevalence of short form of PML-RARa transcripts (bcr3)
was reported (62% of cases), while in de novo APL, the frequency of cases with a short form
varied from 15% to 40-47% (Lin et al., 2004; Douer et al., 2003). On the other hand, in 39% of
t-APL exposed to mitoxantrone (a topoisomerase II poison) and in none of the cases arising
de novo, the translocation breakpoints are tightly clustered in an 8-bp region within PML
intron 6, associated with the synthesis of long (bcr1) (Mistry et al., 2005; Hasan et al., 2010).
In functional assays, this “hot spot” and the corresponding RARA breakpoints were com‐
mon sites of mitoxantrone-induced cleavage by topoisomerase II (Mistry et al.,2005).
As to RARA breakpoints, significant clustering of RARA breakpoints in a 3' region of intron
2 (region B) was found in 65% of t-APL as compared to 28% de novo APLs. Furthermore,
approximately 300 bp downstream of RARA region B contained a sequence highly homolo‐
gous to a topoisomerase II consensus sequence. Biased distribution of DNA breakpoints at
both PML and RARA loci suggests the existence of different pathogenetic mechanisms in t-
APL as compared with de novo APL (Hasan et al., 2010). Furthermore, a significant break‐
point clustering has been also observed in PML and RARA loci, with PML breakpoints lying
outside the mitoxantrone-associated hotspot region in epirubicin-related t-APL, that were
shown to be preferential sites of topo II-induced DNA damage, enhanced by epirubicin
(Mays et al., 2010).
On the other hand, almost all chromosome translocations in leukemia that have been ana‐
lyzed to date show no consistent homologous sequences at the breakpoint with small dele‐
tions and duplications in each breakpoint, and micro-homologies and non-template
insertions at genomic junctions of each chromosome translocation. The size of these dele‐
tions and duplications in the same translocation is much larger in de novo leukemia than in
therapy-related leukemia (Zhang & Rowley, 2006).
6.3. Molecular abnormalities, unrelated to chromosome aberrations
Several molecular abnormalities were identified in both de novo AML and t-AML that are not
a result of chromosome abnormalities, including mainly point mutations and gene tandem du‐
plications. Significant differences in frequency of some of them were reported in t-AML.
Internal tandem duplications (ITD) and point mutations within the tyrosine kinase domain
(TKD) of the FMS-like tyrosine kinase 3 (FLT3) gene are among the most frequent molecular
abnormalities in de novo AML, accounting for more than 22% - 35% of the cases, and show‐
ing significant associations with the presence of a normal karyotype. In contrast, these muta‐
tions are only rarely seen in t-AML (Qian et al., 2010). Interestingly, in a small study of t-
APL, FLT3 mutations were detected in 42% of the patients, an incidence similar to that
found in de novo APL cases (30%) (Chillón et al., 2010). These results and the preferential
use of S-form of PML-RARA transcripts suggest that different molecular mechanisms are in‐
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volved in t-APL compared with de novo APL (Yin et al., 2005). NPM1 and CEBPA muta‐
tions, that are generally associated with favorable prognosis, are also detected with a
significantly lower frequency – 30% to 40-50% and 15-20%, respectively, in de novo AML
compared to 4-5% and less in t-AML (Pedersen-Bjergaard et al., 2007; Kayser et al., 2011).
In contrast, higher incidence in t-AML was reported for TP53 mutations – 20% to 30% versus
10-15% in de novo AML. The spectrum of mutations includes missense mutations in exons
4–8, as well as loss of the wild type allele, typically as a result of a cytogenetic abnormality
of 17p. In t-MDS/t-AML, TP53 mutations are associated with −5/del(5q) and a complex kar‐
yotype (Pedersen-Bjergaard et al., 2007; Qian et al., 2010).
Point mutations in the RUNX1 gene are another mode of genetic alteration in development of
leukemia, in addition to gene rearrangements associated with chromosomal translocation.
Sporadic point mutations are frequently found in three leukemia entities: AML M0 subtype,
MDS-AML, and secondary (therapy-related) MDS/AML. In t-MDS/t-AML, as well as after
atomic bomb radiation exposure, the reported incidence for point mutations was higher (15–
30%), frequently with an association with activating mutations of the RAS pathway, com‐
pared to de novo disease (2-3%). Mutations are commonly located in the N-terminal Runt
homology domain (RHD) or in the C-terminal region including the transactivation domain
(TAD) and could be found in patients treated in alkylating agents (Osato M., 2004). Cases with
RUNX1 mutations usually present as t-MDS, with deletion or loss of chromosome arm 7q and
with subsequent transformation to overt t-AML (Christiansen et al., 2004). In contrast, in de
novo AML, RUNX1 mutations are most frequent in cases with +13, whereas frequencies are
similar in other cytogenetic groups (26%-36%) (Schnittger et al.,2007). No significant differen‐
ces have been reported in regard to NRAS, KRAS, MLL-PTD, PTPN11, JAK2.
To study the frequency and spectrum of molecular abnormalities with a proven or sugges‐
tive role in leukemic transformation in patients with t-AML we analysed 407 consecutive
adult AML patients, diagnosed and treated in our institution, for a 12-years period. Among
them, 26 cases had history for a previous malignancy treated with chemotherapy and/or ra‐
diotherapy which accounts for 6,1% of the cases – 12 (46%) males and 14 (54%) females, at a
mean age of 53.5 years (ranging 22-83 years).AML was diagnosed after radio and/or chemo‐
therapy for solid tumours in 16 (61.5%) of the patients and haematopoietic neoplasms – in 10
(38.5%). Qualitative, semi-quantitative or quantitative real-time Reverse transcription poly‐
merase chain reaction (RT-PCR) was applied in all patients for screening of molecular ab‐
normalities, as follows: (i) fusion transcripts BCR-ABL (P210; P190), PML-RARA, AML1-
ETO, CBFb-MYH11, MLL-AF9, MLL-AF6, DEK-CAN, (ii) internal or partial tandem
duplication of FLT3 (FLT3-ITD) and MLL (MLL-ITD) genes respectively, (iii) aberrant over‐
expression of Survivin, EVI1, BAALC, MLF1, PRAME, MDR1 and AID genes, and type A mu‐
tation of NPM1 gene. At least one molecular marker was detected in all patients. The most
frequent type of molecular abnormalities were the aberrant gene over-expression. Among
the overexpressed genes, MDR1 over-expression was the most common finding. The estab‐
lished frequency (61.5%) was significantly higher compared to that in patients with de novo
AML (25.0%) (Schaich et al., 2004). Molecular equivalents of recurrent translocations accord‐
ing to the WHO classification (2008) were found in 34.6% of the cases [9/26]. The “favoura‐
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ble” fusion transcripts PML-RARA, CBFb-MYH11, AML1-ETO were detected in 30.8% of t-
AML, and their frequency was similar to that reported in de novo AML (Grimwade et al.,
2010). In contrast, the MLL-PTD was significantly more frequent (11.5%) compared to de no‐
vo AML (5.0%) (Patel et al., 2012), while the incidence of FLT3-ITD was significantly lower
(7.7% vs 25-25%) (Kindler et al., 2010). Despite the remarkable heterogeneity of detected mo‐
lecular abnormalities, three groups of t-AML could be defined including: patients with “fa‐
vourable” fusion transcripts,patients with overexpression of multiple “unfavourable” genes,
and patients without a specific pattern (Data presented on Table 5.).
Eight of the patients (30.8%) beared “favourable” fusion transcripts PML-RARA, CBFb-
MYH11, or AML1-ETO mRNA. In addition, PRAME(+) was observed in 3/7 evaluable cases,
as well as FLT3-ITD, Survivin(+) and NPM1 mutation – found in 1 case each. MDR1overex‐
pression was found in 5/8 (62.5%) patients. Interestingly, the patients in this group were sig‐
nificantly younger compared to the remaining patients (41.9 yrs vs 57.8 yrs, respectively).
The analysis identified 7 (26.7%) patients with with multiple “unfavourable” abnormalities -
BAALC and Survivin genes were overexpressed in 7/7 cases, in combination with EVI1 gene
overexpression in 5/7 patients or MLF1 – in 4/7, MLL-PTD – in 2/7, FLT3-ITD - in 1/7. Inter‐
estingly ≥3 concomitant arerrations were detected in 6/7 cases. MDR1 overexpression was
found in all patients. The remaining 11 (42.3%) patients did not show any specific pattern.
Single molecular abnormalities such as MLL-PTD; MLL-AF9; EVI1 gene overexpression, as‐
sociated with Survivin(+) in half of the cases were observed, while MDR1 overexpression
was found in 5/11 (45.4%) patients. Clinical observation revealed 6 cases of early deaths. The
OS was significantly different in the three groups (log rank test p=0.006) being the worst in
patients with with multiple “unfavourable” abnormalities and the best – in the “favoura‐
ble”fusion transcripts group (Balatzenko & Guenova, 2012).
6.4. Cooperating mutations in MDS and AML
According to the model proposed by Deguchi & Gilliland (2002), development of AML is
the consequence of collaboration between at least two broad classes of mutations: (i) class I
mutations which result in constitutively activated tyrosine kinases (gain of function) and
confer a proliferative and/or survival advantage without affecting differentiation - c-KIT
D816, FLT3-ITD; FLT3 D835Y; N- or K-RAS mutations; PTPN11; JAK3; and (ii) class II muta‐
tions that affect genes encoding hematopoietic transcription factors (loss of function) and
serve primarily to impair hematopoietic differentiation - RUNX1-EVI1; RUNX1-ETO; CBFb-
MYH11; MLL fusions; NUP98-HOXA9; C/EBPa; PU.1; NPM1 (Deguchi & Gilliland, 2002;
Stavropoulou et al., 2010). In a recent study of 140 cases of t-AML, 33 (26%) showed evi‐
dence of Class I mutations, 47 (34%) - of Class II mutations, and only 18 (13%) demonstrated
both Class I and Class II mutations (Pedersen-Bjergaardet al., 2006). Several studies confirm
the applicability of the model of collaboration between the classes of mutations in t-AML.
At least 14 different genes have been identified as mutated in t-MDS and t-AML, clustering dif‐
ferently and characteristically in the eight genetic pathways. Class I and Class II mutations are
significantly associated, indicating their cooperation in leukemogenesis (Pedersen-Bjergaard
et al., 2007). Several examples of such cooperative genetic alterations were reported.
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n=8
30.8%
52/m 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
62/f 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
49/f 0 1 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0
23/f 0 0 0 1 0 0 0 0 0 0 0 0 0 1 1 0 1
27/f 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0
72/m 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0
28/m 0 0 1 0 0 0 0 0 0 0 0 0 1 1 0 0 0
22/m 0 0 1 0 0 0 0 0 0 0 0 0 1 1 0 0 0
II
n=7
26.9%
67/f 0 0 0 0 0 0 0 1 0 0 1 1 0 1 1 0 0
48/f 0 0 0 0 0 0 0 0 0 1 1 1 0 1 1 0 1
65/f 0 0 0 0 0 0 0 0 0 1 1 0 0 1 1 0 0
50/f 0 0 0 0 0 0 1 0 0 1 1 1 1 1 1 0 0
30/m 0 0 0 0 0 0 1 0 0 1 1 0 0 1 1 0 1
57/m 0 0 0 0 0 0 0 0 0 1 1 1 0 1 1 0 0
82/m 0 0 0 0 0 0 0 0 0 0 1 0 0 1 1 0 0
III
n=11
42.3%
57/f 0 0 0 0 0 0 0 0 0 1 0 1 0 1 N 0 0
83/m 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0
74/m 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 N
44/f 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0
67/f 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1
47/f 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1
56/m 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0
55/f 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0
68/m 0 0 0 0 0 0 0 0 0 0 0 N 0 0 0 0 0
49/m 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0
41/f 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0
Total 0% 11
.5%
11
.5% 7.7
%
3.8
%
0% 11
.5% 7.7
%
0% 23
.1%
26
.9%
24
.0%
15
.4%
61
.5%
48
.0% 0% 16
%
Table 5. Molecular alterations in therapy-related acute myeloid leukemias. Group I - patients with “favourable” fusion
transcripts, Group II - patients with overexpression of multiple “unfavourable” genes, Group III - patients without a
specific pattern. Abreviations: f – female, m – male, N – not done.
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Mutations of RUNX1 are common in therapy-related myelodysplasia following therapy
with alkylating agents and are significantly associated with deletion or loss of chromosome
arm 7q and with a subsequent leukemic transformation. FLT3 mutation and trisomy 21 are
thought to be second hits in AML with RUNX1 Mutations (Osato M., 2004; Christiansen et
al., 2004). Another example that supported cooperation between Class I and Class II muta‐
tions in leukemogenesis is the report of 4 cases with mutations of the PTPN11 gene; 3 of
which had -7/7q-, 2 cases had rare balanced translocations to chromosome band 21q22 with
rearrangement of the RUNX1 gene and the other two patients had rare balanced transloca‐
tions to chromosome band 3q26 with a rearrangement of the EVI1 gene (Christiansen et al.,
2007). Significant association had also been reported between –5/5q– and p53 mutations and
complex chromosome rearrangements; MLL rearrangements and mutations of NRAS, KRAS
or BRAF; PML-RARA and FLT3-ITD; RUNX1 mutations (Class II) and N-RAS mutation
(Class I); MLL-CBP (Class II) and FLT3-ITD (Class I), etc. (Imagawa et al., 2010). Many of the
associations observed in t-AML, such as the NPM1-FLT3, AML1-cKIT and RARA-FLT3 com‐
binations, have previously been emphasized in de novo AML. According to Pedersen-Bjer‐
gaard et al., 2007, in t-AML, at least 8 alternative genetic pathways have been defined based
on characteristic recurrent chromosome abnormalities: (i) patients with 7q–/–7 but normal
chromosomes 5 and without balanced aberrations, (ii) patients with 5q–/–5, but without bal‐
anced aberrations; (iii) patients with t-AML and balanced translocations involving the chro‐
mosomal band 11q23, resulting in chimeric rearrangements between the MLL gene and one
of its numerous alternative partner genes; (iv) patients with balanced translocations to chro‐
mosome band 21q22 or inv(16); (v) patients with promyelocytic leukemia and chimeric rear‐
rangement of the PML and RARA genes; (vi) patients with chimeric rearrangement of the
NUP98 gene on 11p15; (vii) patients with a normal karyotype; (viii) patients with other, of‐
ten unique chromosome aberrations.
7. Prognostic factors
The diagnosis of therapy-related myeloid leukemia (t-MDS/t-AML) identifies a group of
high-risk patients with multiple and varied poor prognostic features (Larson, 2007), such as
overrepresentation of 11q23 translocations, adverse cytogenetics, including complex and
monosomal karyotypes, and MDR1 gene overexpression, as well as reduced frequency of
“favorable” NPM1, and CEBPA mutations. Besides, frequent comorbidities and cummula‐
tive toxicities, related to previous cytotoxic treatments also contribute to a worse prognosis
compared to de novo AML (D'Alò et al., 2011; Kayser S, et al., 2011). In a recent study, the
outcome of patients with t-AML was significantly inferior in comparison to de novo AML:
the 4-year relapse-free survival (RFS) was 24.5% versus 39.5%; and the 4-year overall surviv‐
al (OS) was of 25.5% versus and 37.9%, respectively (Kayser et al., 2011). During the follow-
up of 109 t-AML patients after treatment for epithelial ovarian carcinoma, a median survival
of 3 months from the time of secondary leukemia diagnosis was found compared to 6 month
in patients with de novo AML (Vay et al., 2011). Schoch et al., 2004 found significantly short‐
er median OS in t-AML than in de novo AML (10 vs 15 months). Within patients with t-
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AML, there were significant correlations between OS and both unfavorable and favorable
cytogenetics, while age and WBC count had no impact on OS (Schoch et al., 2004). The criti‐
cal impact of karyotype on the prognosis was reported by Kern et al., clearly demonstrated
significant differences in the median survival between t-AML patients groups with favora‐
ble karyotype (26.7 months) and unfavorable karyotype (5.6 months) (Kern et al., 2004).
Encouraging results were reported after allogeneic hematopoietic stem cells transplantation
(allo-HSCT). The follow-up of 461 patients with t-MDS or t-AML who underwent allo-HSCT
detected 3-year RFS and OS rates of 33% and 35%, respectively. In a multivariate analysis,
the following risk factors were identified: (1) not being in complete remission at the time of
transplantation, (2) abnormal cytogenetics, (3) higher patients' age and (4) therapy-related
MDS. Using age (<40 years), abnormal cytogenetics and not being in complete remission at
the time of transplantation as risk factors, three different risk groups with OS of 62%, 33%
and 24% could be easily distinguished (Kröger et al., 2009). Similar results were observed by
Litzow et al., 2010. The analysis of outcomes in a total of 868 patients, including t-AML
(n=545) or t-MDS (n=323), revealed disease-free (DFS) and OS of 32% and 37% at 1 year and
21% and 22% at 5 years, respectively. In a multivariate analysis, 4 risk factors with adverse
impacts on DFS and OS were identified: (1) age older than 35 years; (2) poor-risk cytogenet‐
ics; (3) t-AML not in remission or advanced t-MDS; and (4) donor other than an HLA-identi‐
cal sibling or a partially or well-matched unrelated donor. The 5-years survival for subjects
with none, 1, 2, 3, or 4 of these risk factors was 50%, 26%, 21%, 10%, and 4%, respectively
[Litzow et al.,2010].
T-AMLs with “favorable” genetic abnormalities involving CBF-transcription complex -
t(8;21)/RUNX1-ETO and inv(16)/t(16;16)/CBFβ-MYH1 and APL with t(15;17)/PML-RARα are
of particular interest since the reported results concerning the prognostic significance of
these aberrations are contradictory and vary from study to study.
According to some studies these patients have treatment outcome comparable with primary
AML patients (de Witte et al., 2002). Complete remission can be obtained in 85% of inten‐
sively treated patients with inv(16), and in 69% with t(15;17), with a median OS of 29
months in both cytogenetic subgroups, thus the response rates to intensive chemotherapy
are comparable to those of de novo disease (Andersen et al., 2002). Similarly, t-AML with
t(15;17) and t(8;21), treated according to standard protocols, had an outcome similar to de
novo cases, indicating the dominant prognostic role of good karyotypes (D'Alò et al., 2011).
The comparison of clinical and pathologic findings in therapy-related APL and de novo APL
cases revealed abnormal promyelocytes with similar morphologic and immunophenotypic
features, comparable cytogenetic findings, comparable rates of FMS-like tyrosine kinase mu‐
tations, and similar rates of recurrent disease and death, suggesting that secondary APL is
similar to de novo APL and, thus, should be considered distinct from other secondary acute
myeloid neoplasms (Duffield et al., 2012).
In contrast, matched analysis (by age, Eastern Cooperative Oncology Group performance
status, and additional cytogenetic abnormalities) indicated worse OS and event-free survival
(EFS) in patients with therapy-related CBF AML carrying the recurrent chromosomal aber‐
rations inv(16) or t(8;21) – a median OS of 100 weeks compared to 376 weeks in de novo CBF
AMLs (Borthakuret al., 2009). In patients with t-AML and t(8;21), the OS is significantly infe‐
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rior to that of patients with de novo t(8;21) AMLs (19 months vs not reached). These findings
suggest that t(8;21) t-AMLs share many features with de novo AML with t(8;21)(q22;q22),
but the affected patients have a worse outcome (Gustafson et al., 2009). Interstingly, it has
been reported recently that despite that fewer complete remissions are achieved in t-APL
(63.6%) compared to de novo APL (92.5%), this was a result of the higher induction mortali‐
ty rate of 36.4% vs. 7.5%, respectively. No cases of leukemic resistance were seen in either
group. However, OS was also inferior in t-APL compared to de novo APL (51% vs. 84%, re‐
spectively) (Elliott et al., 2012).
8. Treatment
The survival of patients with t-AML is often poor despite prompt diagnosis and treatment.
There is a paucity of prospective treatment data since these patients are often excluded from
frontline chemotherapy trials and turned to best supportive care. However, despite that the
CR rate of t-AML patients (28% up to 50%) has been demonstrated to be inferior to patients
with de novo AML (65-80%), this difference can be attributed to the higher number of pa‐
tients with unfavourable karyotypes. Within cytogenetically defined subgroups, the progno‐
sis of t-AML patients does not differ significantly from patients with de novo AML.
Treatment recommendations should be further based on the patient’s performance status,
which likely reflects age, comorbidities, the status of the primary disease, and the presence
of complications from primary therapy, as well as the clonal abnormalities detected in the t-
AML cells. Standard chemotherapy, haematopoietic stem cell transplantation, as well as ex‐
perimental trials are applied.
Figure 1. Clinical algorythm in the management of t-AML patients.
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Intriguingly, several studies found that results after induction therapy were not different be‐
tween t-AML and de novo AML patients. Furthermore, analyses of CR-rates, OS and DFS,
when corrected for the influence of age, cytogenetic abnormalities, performance status and
leucocyte count, showed that the presence of a t-AML may even lose prognostic significance
and patients with secondary AML should be offered the chance of benefiting from treatment
according to current frontline AML protocols (Ostgård et al., 2010). The dosage and modali‐
ty of treatment during postremission therapy however have a marked impact on the cumu‐
lative toxicity of cancer therapy. Therefore, intensive induction therapy should not be
withheld for t-AML patients, and dose-reduced regimes for allogeneic HSCT should be con‐
sidered. In contrast, t-AML patients >60 years show a significantly greater relapse rates
probably due to the lower dosage of applied chemotherapy during postremission therapy
compared with younger patients (Kayser et al., 2011). Encouraging results are reported after
allogeneic transplantation. The identification of relevant risk factors allows for a more pre‐
cise prediction of outcome and identification of subjects most likely to benefit from allogene‐
ic transplantation.Allogeneic transplantation should be proposed timely to these patients
after an accurate analysis of patient history (Litzow et al., 2010; Spina et al., 2012). Novel
transplantation strategies using reduced intensity conditioning regimens as well as novel
drugs – demethylating agents and targeted therapies, await clinical testing and may im‐
prove outcome (de Witte et al., 2002).
9. Conclusion
As the number of patients with t-AMLs is expected to rise, safety issues of cytotoxic thera‐
pies are becoming increasingly important in order to develop strategies to reduce the risk
for therapy-related malignancies without compromising success rates for the respective pri‐
mary disorders. Besides, there is clinical and biological overlap between therapy related and
high-risk de novo leukaemias suggesting similar mechanisms of leukaemogenesis. Deeper
insights into pathogenetic mechanisms will eventually help to establish a more differentiat‐
ed clinical approach to successfully treat, but hopefully also prevent, these often fatal conse‐
quences of cytotoxic therapies.
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